US clears Sanofi’s ‘follow-on’ insulin Admelog

The US Food and Drug Administration has cleared Sanofi's Admelog, the first follow-on biologic version of Eli Lilly’s Humalog, to manage mealtime blood sugar levels in people with diabetes. Admelog is a short-acting insulin approved on the back of a clinical development programme involving more than 1,000 adults living with type I or type II diabetes. According to the Centers for Disease Control and Prevention, more than 30 million people in the US have diabetes. “Admelog will offer a more affordable option for those who require control of their blood sugar levels at mealtime," said Stefan Oelrich, executive vice president and head of Global Diabetes and Cardiovascular at Sanofi.